Recro Pharma (REPH) Misses Q1 EPS by 30c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact
May 11, 2020 7:01 AM EDTCompany Generates $21.8 Million in First Quarter 2020 Revenues
Revises Annual Revenue Guidance for 2020
MALVERN, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today reported financial results for the three months ended March 31, 2020.
In this challenging and unprecedented time, U.S. pharmaceutical product manufacturing has never been more essential,... More
